The European Directorate for the Quality of Medicines (EDQM) has approved Jeil Pharmaceutical’s active pharmaceutical ingredient called cefpodoxime proxetil, the company said Tuesday.
The company has aimed to obtain the European body’s Certificates of Suitability (CEP) for their antibiotic ingredient since April 2015. The recent European approval will set the grounds for the company’s intended entry into the European market, it said.
|Jeil’s Baegam manufacturing plant located in Yongin, Gyeonggi Province|
“The EDQM approval proves the superiority of Jeil’s cephalosporins antibiotic products, and we plan to advance into the European market actively,” a company official said.
Jeil produces its antibiotics in its Baegam Plant in Yongin, Gyeonggi Province.
Cefpodoxime proxetil is an active pharmaceutical ingredient (API), which serves as a drug’s raw ingredient to make antibiotic treatments for infectious diseases. The API is used to make cephalosporins, a class of β-lactam antibiotics.
<© Korea Biomedical Review, All rights reserved.>